CEO Discloses 5.03% Stake in BioVie Amidst 'Going Concern' Warning
BIVI sits 24% above its 52-week low of $1.06 on light trading volume (0.3× avg).
Summary
BioVie Inc.'s CEO, Cuong Do, and his investment entity have filed an initial Schedule 13D, disclosing a combined beneficial ownership of 5.03% of the company's Class A Common Stock, including shares, options, and warrants.
Key Events · Ownership and Investor Activity · BIVI
-
CEO Discloses Significant Stake
Cuong Do, President and CEO of BioVie Inc., along with Do & Rickles Investments, LLC, has filed an initial Schedule 13D, reporting a beneficial ownership of 5.03% of the company's Class A Common Stock.
-
Ownership Details
The reported stake includes 907 shares held directly by Mr. Do, 9,992 shares held by Do & Rickles Investments, LLC, warrants to purchase 5,050 shares, and stock options to purchase 383,069 shares.
-
No Recent Transactions
The filing explicitly states that the Reporting Persons did not engage in any transactions in the company's common stock during the past 60 days.
-
Investment Purpose
The securities are held for investment purposes, with the Reporting Persons intending to continuously review their investment and potentially adjust their position in the future.
Analysis · BIVI · Life Sciences
This initial Schedule 13D formally discloses CEO Cuong Do's significant personal stake in BioVie Inc., totaling 5.03% of the outstanding Class A Common Stock on a fully diluted basis. While the filing explicitly states no new transactions occurred in the past 60 days, this disclosure is particularly notable given the company's recent 'going concern' warning and prior dilutive offering. The CEO's substantial beneficial ownership, which includes shares, options, and warrants, aligns his financial interests directly with those of shareholders. This personal commitment is an important signal for investors, especially as the company navigates ongoing challenges, including lawsuits related to its Alzheimer's trial.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIVI was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.06 to $13.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.